Member Info for Aether

The term "pregnant women" isn't creepy, hold4results.

"The RECOVER initiative will soon announce clinical trials, leveraging data from clinicians and patients in which symptom clusters were identified and can be targeted by various interventions. These trials will investigate therapies that are indicated for other non-COVID conditions and novel treatments for Long COVID."

Will this include drugs that have not yet been authorised by the relevant regulatory authority?

From the website:

"To understand Long COVID fully, hundreds of RECOVER investigators are recruiting more than 17,000 adults (including pregnant people)"

I thought only females could get pregnant?

Nevertheless, interesting news.

Wigster says:

"If we don't / can't get on a trial like this then you've really got to question whether there's something sinister afoot..."

Ghia

What do you think Poly's rationale is for their actions?

Thank you.

It's still true.

We will know whether we are on a trial by December/January.

If we're not, we have enough money through 2023.

Then, it's lights out or a fund raise.

We'll know by the new year whether there will be a clinical trial.

If not, it's lights out in 12 months or a fund raise.

Doc - posts crossed.

Excellent post.

"... for by then we'd all have to accept that Govt trial regulators and Big Pharma's acquisitions departments might conceivably know more about the commercial prospects of SNG than Polygon or even Tommyd.

Hopefully we don't get to this domesday scenario but if RM sits in that Proactive chair again to announce another fundraise, the game will be well and truly up."

Two days ago, I emailed Brooke Clarke about whether winter dosing was still expected. So far, no reply!

I would not trust Synairgen to run their own clinical trial again after the last two debacles.

We have until December to see if we are included in a PT otherwise I'd assume we won't be and there'll be a fundraiser within 12 months.

cmww2014

I'm not so sure.

This isn't a normal TO situation. A lot of people have lost a lot of money and this is still an AIM stock with no commercialised product.

If we aren't included in a trial we have 12 months before it's lights out or a fund raise.

In the background, there is economic uncertainty in the market, and the possibility of a market correction on the scale of 2008.

I suspect if the offer is reasonable (not even good!) then enough people will sell.

If that is the, or one of their, plans, they can offer 17p per share but it is unlikely enough investors will accept that price; so, they will gradually have to increase their offer to entice more investors to part with their shares.

It would be interesting to consider how much it would take to reach 90% for a TO.

Make an offer price at a reasonable exit price for averaged down investors to sell their shares.

A hard core will never sell, however, is that hard core 10% of the shareholders?

If it isn't, then there will be a TO if Polygon guage the offer price correctly.

How much? 50p or 75p or 100p?

Polygon are still confident in the product; hence, the continued buying spree and RNS.

However, will SNG be included on a clinical trial soon?

If it isn't, the share price will drift and this will accelarte as we progress into 2023.

Then there will be 12 months and it's lights out without a fund raise.

Why are Polygon still buying?

Green bin it.

Don't feed it.

From its posting history, it's obvious it's got a personality disorder or mentally ill. Bin it with the other dross.

How long does it usually take to get a reply back from Ms Brooke Clarke?

Two days ago, I sent an email asking whether RM still expected to be dosing patients this winter.

So far, no reply!

:D

That's not his "role".

He's obviously a weary and concerned private investor.

There are, I suspect, genuine derampers.

He isn't one of them.

The forum needs balance based on reasonable and genuine opinions.

Otherwise, it's just a cult.

Doc83,

I would not wait until trial completion again.

Instead, I would wait a while during the trial in anticipation of a T/O.

Polygon the major institutional investor just INCREASED its holding.

The deep dive data clearly shows this is not a complete flop.

The NIH states in the analysis of the Activ-2 P2 data that there should be another clinical trial.

*IF* this gets on another trial, with the deep dive and bio-bank data, this should be taken over by BP and investors recoup some of their initial investment.

I've averaged down, When/If I reach my break-even, I'm out.

If we don't get on a platform trial, we have 12 months before the lights go out or there's another fund raiser.

But if we do get on a platform trial, this heads north sharply.

The share price will continue to drift without further news.

Yes, but they still didn't predict the Sprinter results...

Maybe, with their resources, they have heard something or maybe they are just buying at the lowest possible price.

Either way, it is a positive that, at the moment, they still seem positive about SNG.

It is also instructive to examine how they have dealt with situations like this previously.

"...(bearing in mind that this is increasingly looking like a longer term investment)? "

Yes, it is looking like a longer term investment.

If we don't get onto a PT this winter, there will probably be a fund raise in 12 months.

This share is too risky now and I would not trust Synairgen to run another trial.

On the other hand, if we do get on a PT or JV this heads north sharply and I'm out.

There is a major market correction coming and if you're in cash it will be possible to buy solid blue chip companies relatively cheaply especially if the correction is on the scale of 2008-2009. Time to be free of this cult share.

The stopgap funding agreement to keep the government open past Friday does not have the Biden administration’s requested funding for monkeypox or COVID-19. Earlier this month, the White House asked for $22.4 billion for COVID-related needs and $4.5 billion for monkeypox.

White House Press Secretary Karine Jean-Pierre was asked during a briefing on Tuesday if the White House has given up on that funding? “Our near-term priority is keeping the government open -- we've been very clear about that,” she replied. “We've been very clear since early 2022 about our COVID funding needs and have warned that, without congressional action, we would be forced…to make difficult trade-offs.”

Already, there have been cuts to the testing program and “being unable to take action that Republicans and Democrats support to have the United States lead the effort on the next generation of vaccine, the next generation of treatments,” Jean-Pierre noted. “And so, we're not going to give up.”